Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Avadel Pharmaceuticals plc (Nasdaq: AVDL) will present its investigational drug FT218 at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit from September 21-23, 2020. CEO and executives will discuss FT218, a once-nightly formulation of sodium oxybate for narcolepsy, on September 22, 2020, from 10:50 a.m. to 11:30 a.m. ET. The presentation will be webcast live and available for later viewing. Management will also engage in one-on-one meetings with registered investors.
- None.
- None.
DUBLIN, Ireland, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place September 21 – 23, 2020.
| Presentation details: | |
| Date: | Tuesday, September 22, 2020 |
| Time: | 10:50 a.m. – 11:30 a.m. ET |
| Webcast: | A live and archived webcast of the presentation will be available at (click here) or on the Company’s website (click here) |
In addition, management will be participating in one-on-one meetings with investors who are registered to attend the conference.
About Avadel Pharmaceuticals plc:
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.
About FT218
FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. In March of 2020, the Company completed the REST-ON study, a pivotal, double-blind, randomized, placebo-controlled Phase 3 trial, to assess the efficacy and safety of FT218 in the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. FT218 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. The designation was granted on the plausible hypothesis that FT218 may be clinically superior to the twice-nightly formulation of sodium oxybate already approved by the FDA for the same indication. In particular, FT218 may be safer due to ramifications associated with the dosing regimen of the previously approved product.
Contacts:
| Investor Contacts |
| Tom McHugh |
| Chief Financial Officer |
| Phone: (636) 449-1843 |
| Email: tmchugh@avadel.com |
| Tim McCarthy |
| LifeSci Advisors, LLC |
| Phone: (212) 915-2564 |
| Email: tim@lifesciadvisors.com |
| Media Contact |
| Patrick Bursey |
| LifeSci Communications, LLC |
| Phone: (646) 970-4688 |
| Email: pbursey@lifescicomms.com |
FAQ
When will Avadel Pharmaceuticals present at the Oppenheimer Summit?
What is FT218 developed by Avadel Pharmaceuticals?
Where can I watch the Avadel Pharmaceuticals presentation?
What type of meetings will Avadel Pharmaceuticals conduct at the conference?
What is the purpose of FT218?
